Corcept Therapeutics Incorporated CORT
At closeNov 4, 2026, 5:30 PM EST
After hours · Nov 4, 5:30 PM ET
- YTD
- +127.64%
- 1 year
- +11.42%
- Market cap
- 8.56B
- Revenue (ttm)
- 830.81M
- Profit margin
- 6.64%
- EPS (ttm)
- 0.45
- Shares out
- 108.10M
- P/E ratio
- 176.04
- Forward P/E
- 18.77
- YTD return
- +127.64%
- 1-year return
- +11.42%
- Volume
- 2.20M
- Avg volume
- 1.17M
- Open
- 84.98
- Previous close
- 81.93
- Day's range
- 71.29 – 84.98
- 52-week range
- 28.66 – 126.38
- Beta
- 0.56
- Analysts
- Buy
- Price target
- 141.00 (+78.0%)
- Earnings date
- Feb 23, 2027
5D -7.47 (-8.62%)
Key statistics
- Enterprise value
- 8.56B
- PEG ratio
- 0.81
- Price / sales
- 10.31
- Price / book
- 12.96
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 31.70%
- Free cash flow
- 77.40M
- Total cash
- 308.20M
- Total debt
- 9.42M
- Return on equity
- 8.23%
- Short % of float
- 10.24%
- 50-day average
- 110.31
- 200-day average
- 75.23
Analyst view
Consensus: buy
- Target (low)
- 50.00
- Target (mean)
- 141.00
- Target (high)
- 165.00
- Strong buy1
- Buy3
- Hold0
- Sell1
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 1.20.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 1.13 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | 0.794 | 1.01 | +0.22 | +27.20% |
| Jul 29, 2026 | Jun 30, 2026 | 0.02427 | 0.36 | +0.34 | +1,383.31% |
| Apr 30, 2026 | Mar 31, 2026 | -0.11019 | -0.30 | -0.19 | -172.26% |
| Feb 24, 2026 | Dec 31, 2025 | 0.33 | 0.20 | -0.13 | -39.39% |
| Nov 4, 2025 | Sep 30, 2025 | 0.18 | 0.16 | -0.02 | -11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Sep 18, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 30, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Jul 30, 2026 | Canaccord Genuity | main | Buy | Buy |
| Jul 30, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 29, 2026 | Canaccord Genuity | main | Buy | Buy |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- corcept.com
News
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173 
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues 
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript 
Corcept Therapeutics Q3 Earnings Call Highlights 
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates 
Corcept Therapeutics Q3 2026 Earnings Call Transcript 
Corcept Therapeutics Affirms FY2026 Sales Guidance of $1.100B-$1.200B vs $1.146B Est 
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update 
Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study 
Corcept Therapeutics Announces Results From Part A Of Its Phase 2 BELLA Trial Of Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab In Patients With Ovarian Cancer; Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab Demonstrated Clinically Meaningful Progression-Free Survival, Objective Response Rate And Overall Survival
Your note
Sign in to keep a note on CORT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER GEORGE LEONARD JR. | Director | Purchase | Mar 16, 2026 | 5,550,200 |
| BELANOFF JOSEPH K | Chief Executive Officer | Sale | May 31, 2026 | 0 |
| GUYER WILLIAM | Officer | Stock Award(Grant) | Aug 31, 2026 | 4,313 |
| HUNT HAZEL | Officer | Conversion of Exercise of derivative security | Feb 8, 2026 | 255,437 |
| LYON JOSEPH DOUGLAS | Chief Technology Officer | Sale | Oct 1, 2026 | 5,683 |
| MADUCK SEAN | Officer | Sale | Oct 1, 2026 | 119,655 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 11.50% | 12,432,023 | 984.86M | Jun 29, 2026 |
| Ingalls & Snyder LLC | 7.34% | 7,934,507 | 628.57M | Jun 29, 2026 |
| Renaissance Technologies, LLC | 4.87% | 5,261,628 | 416.83M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.67% | 5,044,638 | 399.64M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.86% | 4,172,482 | 330.54M | Jun 29, 2026 |
| Parallel Advisors, LLC | 3.61% | 3,902,544 | 309.16M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.13% | 3,388,420 | 268.43M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 2,893,842 | 229.25M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.94% | 2,093,441 | 165.84M | Jun 29, 2026 |
| Fidelity Contrafund | 1.35% | 1,464,100 | 115.99M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.12% | 1,205,900 | 95.53M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.01% | 1,095,943 | 86.82M | Jun 29, 2026 |